IMM 7220
Alternative Names: IMC-010; IMM7220Latest Information Update: 11 Sep 2025
At a glance
- Originator ImmuneOnco Biopharma
- Class Bispecific antibodies; Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Activin receptor antagonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 01 May 2025 Preclinical trials in Obesity in China (unspecified route)